Keynote 966 Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Keynote 966 trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Keynote 966 Trial Today - Breaking & Trending Today

European Commission Approves New Frontline Indications for Pembrolizumab Plus Chemo in Select GI Cancers

The European Commission has approved new indications for pembrolizumab in combination with chemotherapy in select patients with gastric or gastroesophageal adenocarcinoma and select patients with biliary tract cancer. ....

European Union , European Commission , Merck Research Laboratories , Eligibility Criteria , Gastric Cancer , Gastroesophageal Cancer , Biliary Tract Carcinoma , Gi Cancers , Gastrointestinal Cancers , Keynote 859 Trial , Keynote 966 Trial ,

FDA Approval Sought for Pembrolizumab Plus Chemotherapy in Biliary Tract Cancer

The FDA has accepted for review a supplemental biologics license application seeking the approval of pembrolizumab plus standard chemotherapy comprised of gemcitabine and cisplatin for use in patients with locally advanced unresectable or metastatic biliary tract cancer. ....

Scot Ebbinghaus , Merck Research Laboratories , Prescription Drug User Fee , Pembrolizumab Plus Gemcitabine And Cisplatin , Patients With Locally Advanced Unresectable Or Metastatic Biliary Tract Cancer , Keynote 966 Trial ,